More on Eli Lilly (LLY -1.7%) Q3: net profit +7% to $1.33B, boosted by payment from former...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

More on Eli Lilly (LLY -1.7%) Q3: net profit +7% to $1.33B, boosted by payment from former partner Amylin. Sales breakdown: antidepressant Cymbalta +16% to $1.24B, cancer drug Alimta +2% to $643.6M. Antipsychotic Zyprexa -68% to $374.5M, due to patent loss; animal-health products +6% to $479.4M. Reiterates 2012 guidance.